Variant Gene Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
dbSNP: rs121434569
rs121434569
0.100 GeneticVariation BEFREE Repeat biopsy procedures and T790M rates after afatinib, gefitinib, or erlotinib therapy in patients with lung cancer. 30885357

2019

dbSNP: rs121434569
rs121434569
0.100 GeneticVariation BEFREE In this study, we applied ORNi-PCR to simultaneous detection of the de novo L858R and acquired T790M mutations in the <i>EGFR</i> gene in lung cancer cells. 31426517

2019

dbSNP: rs121434569
rs121434569
0.100 GeneticVariation BEFREE EGFR T790M detection in formalin-fixed paraffin-embedded tissues of patients with lung cancer using RNA-based in situ hybridization: A preliminary feasibility study. 31407509

2019

dbSNP: rs121434569
rs121434569
0.100 GeneticVariation BEFREE Although afatinib inhibited the growth of lung cancer cells with low T790M allele frequencies in preclinical studies, this could not be translated into clinical efficacy in terms of lowering the rate or delaying the time of T790M acquisition. 31030101

2019

dbSNP: rs121434569
rs121434569
0.100 GeneticVariation BEFREE A 79-year-old woman had disease progression during third-line treatment with osimertinib for an EGFR L858R/T790M-mutant lung cancer. 31254668

2019

dbSNP: rs121434569
rs121434569
0.100 GeneticVariation BEFREE Its clinical utility has been well demonstrated for EGFR T790M testing in lung cancer patients suffering progress after tyrosine kinase inhibitor treatment. 31620244

2019

dbSNP: rs121434569
rs121434569
0.100 GeneticVariation BEFREE Of the 12 cases of NTRK1+ lung cancer, 6 had had concurrent activating EGFR mutations and/or had received previous treatment with EGFR tyrosine kinase inhibitors (TKIs), with 2 having concurrent EGFR T790M and 1 additional EGFR C797S. 31761448

2019

dbSNP: rs1057519847
rs1057519847
0.100 GeneticVariation BEFREE Front-line epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) therapy is the standard of care for lung cancer patients with sensitising EGFR mutations (exon 19 deletion or L858R mutation). 29462253

2018

dbSNP: rs1057519847
rs1057519847
0.100 GeneticVariation BEFREE This CLN-Ohi-MB biochip could quantify single-point mutations in KRAS mRNA (G12C, G12D, G12V) in pancreatic cancer cell-derived EVs and single-point mutations in EGFR mRNA (L858R and T790M) in lung cancer cell-derived EVs with high specificity, not achievable by conventional molecular probes. 30145409

2018

dbSNP: rs1057519847
rs1057519847
0.100 GeneticVariation BEFREE The most frequent epidermal growth factor receptor (EGFR) mutations of lung cancer include exon 19 in deletion and the exon 21 L858R mutation. 29290255

2018

dbSNP: rs1057519847
rs1057519847
0.100 GeneticVariation BEFREE Intratumoral heterogeneity of copy number variation in lung cancer harboring L858R via immunohistochemical heterogeneous staining. 30268468

2018

dbSNP: rs1057519847
rs1057519847
0.100 GeneticVariation BEFREE Specific targeting of point mutations in EGFR L858R-positive lung cancer by CRISPR/Cas9. 29748615

2018

dbSNP: rs1057519847
rs1057519847
0.100 GeneticVariation BEFREE Diagnosis of EGFR exon21 L858R point mutation as lung cancer biomarker by electrochemical DNA biosensor based on reduced graphene oxide /functionalized ordered mesoporous carbon/Ni-oxytetracycline metallopolymer nanoparticles modified pencil graphite electrode. 29753165

2018

dbSNP: rs1057519848
rs1057519848
0.100 GeneticVariation BEFREE Specific targeting of point mutations in EGFR L858R-positive lung cancer by CRISPR/Cas9. 29748615

2018

dbSNP: rs1057519848
rs1057519848
0.100 GeneticVariation BEFREE The most frequent epidermal growth factor receptor (EGFR) mutations of lung cancer include exon 19 in deletion and the exon 21 L858R mutation. 29290255

2018

dbSNP: rs1057519848
rs1057519848
0.100 GeneticVariation BEFREE This CLN-Ohi-MB biochip could quantify single-point mutations in KRAS mRNA (G12C, G12D, G12V) in pancreatic cancer cell-derived EVs and single-point mutations in EGFR mRNA (L858R and T790M) in lung cancer cell-derived EVs with high specificity, not achievable by conventional molecular probes. 30145409

2018

dbSNP: rs1057519848
rs1057519848
0.100 GeneticVariation BEFREE Front-line epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) therapy is the standard of care for lung cancer patients with sensitising EGFR mutations (exon 19 deletion or L858R mutation). 29462253

2018

dbSNP: rs1057519848
rs1057519848
0.100 GeneticVariation BEFREE Intratumoral heterogeneity of copy number variation in lung cancer harboring L858R via immunohistochemical heterogeneous staining. 30268468

2018

dbSNP: rs1057519848
rs1057519848
0.100 GeneticVariation BEFREE Diagnosis of EGFR exon21 L858R point mutation as lung cancer biomarker by electrochemical DNA biosensor based on reduced graphene oxide /functionalized ordered mesoporous carbon/Ni-oxytetracycline metallopolymer nanoparticles modified pencil graphite electrode. 29753165

2018

dbSNP: rs121434568
rs121434568
0.100 GeneticVariation BEFREE Diagnosis of EGFR exon21 L858R point mutation as lung cancer biomarker by electrochemical DNA biosensor based on reduced graphene oxide /functionalized ordered mesoporous carbon/Ni-oxytetracycline metallopolymer nanoparticles modified pencil graphite electrode. 29753165

2018

dbSNP: rs121434568
rs121434568
0.100 GeneticVariation BEFREE The most frequent epidermal growth factor receptor (EGFR) mutations of lung cancer include exon 19 in deletion and the exon 21 L858R mutation. 29290255

2018

dbSNP: rs121434568
rs121434568
0.100 GeneticVariation BEFREE Front-line epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) therapy is the standard of care for lung cancer patients with sensitising EGFR mutations (exon 19 deletion or L858R mutation). 29462253

2018

dbSNP: rs121434568
rs121434568
0.100 GeneticVariation BEFREE This CLN-Ohi-MB biochip could quantify single-point mutations in KRAS mRNA (G12C, G12D, G12V) in pancreatic cancer cell-derived EVs and single-point mutations in EGFR mRNA (L858R and T790M) in lung cancer cell-derived EVs with high specificity, not achievable by conventional molecular probes. 30145409

2018

dbSNP: rs121434568
rs121434568
0.100 GeneticVariation BEFREE Intratumoral heterogeneity of copy number variation in lung cancer harboring L858R via immunohistochemical heterogeneous staining. 30268468

2018

dbSNP: rs121434568
rs121434568
0.100 GeneticVariation BEFREE Specific targeting of point mutations in EGFR L858R-positive lung cancer by CRISPR/Cas9. 29748615

2018